Author/Authors :
Dvir، نويسنده , , Danny and Waksman، نويسنده , , Ron and Barbash، نويسنده , , Israel M. and Kodali، نويسنده , , Susheel K. and Svensson، نويسنده , , Lars G. and Tuzcu، نويسنده , , E. Murat and Xu، نويسنده , , Ke and Minha، نويسنده , , Saʹar and Alu، نويسنده , , Maria C. and Szeto، نويسنده , , Wilson Y. and Thourani، نويسنده , , Vinod H. and Makkar، نويسنده , , Raj and Kapadia، نويسنده , , Samir and Satler، نويسنده , , Lowell F. and Webb، نويسنده , , John G. and Leon، نويسنده , , Martin B. and Pichard، نويسنده , , Augusto D.، نويسنده ,
Abstract :
Objectives
udy aimed to evaluate the impact of chronic lung disease (CLD) on outcomes of severe aortic stenosis patients across all treatment modalities.
ound
es of patients with CLD undergoing transcatheter aortic valve replacement (TAVR) have not been systematically examined.
s
tients who underwent TAVR in the PARTNER (Placement of AoRTic TraNscathetER Valve) trial, including the continued access registry (n = 2,553; 1,108 with CLD), were evaluated according to CLD clinical severity. Additionally, outcomes of CLD patients included in the randomization arms of the PARTNER trial were compared: Cohort A patients (high-risk operable) treated by either TAVR (n = 149) or surgical aortic valve replacement (SAVR); (n = 138); and Cohort B patients (inoperable) treated by either TAVR (n = 72) or standard therapy only (n = 95).
s
all TAVR-treated patients, at 1-year follow-up, patients with CLD had higher mortality than those without it (23.4% vs. 19.6%, p = 0.02). Baseline characteristics of CLD patients who underwent TAVR were similar to respective controls. In Cohort A, 2-year all-cause death rates were similar (TAVR 35.2% and SAVR 33.6%, p = 0.92), whereas in Cohort B, the death rate was lower after TAVR (52.0% vs. 69.6% after standard therapy only, p = 0.04). Independent predictors for mortality in CLD patients undergoing TAVR included poor mobility (6-min walk test <50 m; hazard ratio: 1.67, p = 0.0009) and oxygen-dependency (hazard ratio: 1.44, p = 0.02). Although CLD patients undergoing TAVR have worse outcomes than patients without CLD, TAVR is better in these patients than standard therapy and is similar to SAVR.
sions
gh patients with CLD undergoing TAVR had worse outcomes than patients without CLD, TAVR performed better in these patients than standard therapy and was similar to SAVR. However, CLD patients who were either poorly mobile or oxygen-dependent had poor outcomes. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894)
